Study to Evaluate Multiple Doses of ERB-041 in Healthy, Female Japanese Subjects

Phase 1

Completed

• Conditions: Healthy

• Registration Number: NCT00434187
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

The primary objective is evaluate the safety, tolerability, and pharmacokinetics of multiple doses of ERB-041, an investigational drug, in healthy, female Japanese subjects.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-08
• Study Completion: 2006-10
• Study First Submitted: 2007-02-09
• Study First Submitted QC: 2007-02-12
• Study First Posted: 2007-02-13
• Status Verified: 2009-07
• Last Update Submitted: 2009-07-08
• Last Update Posted: 2009-07-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 24

Inclusion Criteria

• Healthy as determined by the investigator on the basis of medical history and screening evaluations.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
safety, pharmacokinetics